To obtain access to any datasets listed on this site, you must first receive approval from NIDA Datashare's Data Access Committee (DAC).

Please submit your request by sending your request to NIDA_Datashare_DAC@nih.gov along with the following information:

Your name, title, and organization
Study Number and Study Title
The specific dataset(s) you are requesting
The intended use or purpose of the data
Willingness to comply with the NIDA Datashare Registration Agreement

Once your request is reviewed, you will receive instructions on how to proceed.

Thank you for your cooperation.

NIDA-CTO-0007

Division

DTMC

HEAL Study

Investigator(s)

Steven Shoptaw, Ph.D.

Thomas F. Newton, M.D.

Title

Phase 2, Double-Blind, Placebo-Controlled Trial Of Cabergoline For The Treatment Of Cocaine Dependence

Short Description

To assess the efficacy and safety of cabergoline in reducing cocaine use in subjects with cocaine dependence. It is hypothesized that cabergoline treatment, compared to placebo, will be associated with fewer days of cocaine use as assessed by self-report confirmed with urine assays for benzoylecgonine (BE).

Release Date

Dec 21, 2017

Description

The primary objective of this study is to assess the efficacy of cabergoline in reducing cocaine use in subjects with cocaine dependence (DSM-IV criteria). The hypothesis is that cabergoline will increase the weekly mean proportion of cocaine non-use days over the treatment period as compared to placebo as determined by self-report of cocaine use confirmed with urine assays for BE.

Keywords

Assessments

Addiction Severity Index Lite

Brief Substance Craving Scale

Clinical Global Impression Scales

Cocaine Craving Questionnaire - Now

Substance Use Report

Urine Cocaine Level